A partial dose of the polio vaccine works just as well as a full one in providing a basic level of immunity against the disease, a new study shows.
Analysts expect the U.S. vaccine market to rack up to $12.8 billion in sales for 2012. And Transparency Market Research says the industry can expect to see 5.3% growth through 2018. But low vaccination rates among U.S. adults may hamper that upward trend.
Just more than a year after putting a voluntary moratorium on certain experiments involving the H5N1 avian influenza virus, researchers say the studies should restart.
Almost half of all babies and toddlers in the United States aren't receiving vaccines on time, a new study shows.
Many drug developers have tried and all have failed to create a vaccine for potentially fatal, flu-like dengue. And now the stakes are higher, as the World Health Organization just deemed dengue the world's fastest-spreading tropical disease, representing a pandemic threat.
A fast, early and widespread flu season has gripped the United States, though deaths and hospitalizations are still below pandemic thresholds.
NIH's National Institute of Allergy and Infectious Diseases has its eye on Altravax, awarding the company $1.2 million to advance a dengue vaccine and hepatitis B therapeutic.
Pfizer has always harbored substantial goals for its pneumococcal conjugate vaccine, and the pharma giant got a leg up Tuesday when the European Commission approved the use of Prevenar 13 in older children and adolescents.
A typhoid vaccine recall issued back in October by Sanofi Pasteur MSD--a joint venture of pharma giants Sanofi and Merck--has resulted in a shortage of the injection in the United Kingdom.
The Serum Institute of India will donate 20 million doses of measles-rubella vaccine to the GAVI Alliance as part of that organization's initiative to reduce the mortality rate caused by measles-rubella in the developing world.